← Back to Search
ErbB-targeted Therapeutic Approaches In Human Cancer.
Published 2003 · Biology, Medicine
Save to my Library
Download via 🐼 PaperPanda Download via oaDOI Download via OAB Download via LibKey Download via Google Google ScholarAnalyze on Scholarcy Visualize in Litmaps
Reduce the time it takes to create your bibliography by a factor of 10 by using the world’s favourite reference manager
Time to take this seriously.
The overexpression and aberrant function of the epidermal growth factor receptor (EGFR, erbB1, HER1) and its ligands and coreceptors in a wide spectrum of epithelial cancers have provided a rationale for targeting this signaling network with novel treatment approaches. Several antireceptor therapeutic strategies have been pursued, but two stand ahead in their clinical development. One approach has been the generation of small molecules that compete with adenosine triphosphate (ATP) for binding to the receptor's kinase pocket, thus blocking receptor activation and the transduction of postreceptor signals. The second approach utilizes humanized monoclonal antibodies generated against the receptor's ligand-binding extracellular domain. These antibodies block binding of receptor-activating ligands and, in some cases, can induce receptor endocytosis and downregulation. Clinical studies already suggest that both of these approaches, either alone or in combination with standard anticancer therapies, are well tolerated and can induce clinical responses and tumor stabilization in a variety of common carcinomas.
This paper references
Biological effects in vitro of monoclonal antibodies to human epidermal growth factor receptors.
J. Sato (1983)
Growth inhibition of human tumor cells in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies.
H. Masui (1984)
Relation of epidermal growth factor receptor concentration to growth of human epidermoid carcinoma A431 cells.
T. Kawamoto (1984)
Tumor growth modulation by a monoclonal antibody to the epidermal growth factor receptor: immunologically mediated and effector cell-independent effects.
U. Rodeck (1987)
Epidermal growth factor receptors in breast cancer: association with early relapse and death, poor response to hormones and interactions with neu.
A. Harris (1989)
Phase I and imaging trial of indium 111-labeled anti-epidermal growth factor receptor monoclonal antibody 225 in patients with squamous cell lung carcinoma.
C. Divgi (1991)
Ligand-induced activation of A431 cell epidermal growth factor receptors occurs primarily by an autocrine pathway that acts upon receptors on the surface rather than intracellularly.
M. J. van de Vijver (1991)
Anti-oncogenic activity of signalling-defective epidermal growth factor receptor mutants.
N. Redemann (1992)
Structural alterations of the epidermal growth factor receptor gene in human gliomas.
A. Wong (1992)
Regulation of epidermal growth factor receptor in NIH3T3/HER14 cells by antireceptor monoclonal antibodies.
Z. Fan (1993)
Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung.
V. Rusch (1993)
Mice with a null mutation of the TGFα gene have abnormal skin architecture, wavy hair, and curly whiskers and often develop corneal inflammation
G.Bruce Mann (1993)
Blockade of epidermal growth factor receptor function by bivalent and monovalent fragments of 225 anti-epidermal growth factor receptor monoclonal antibodies.
Z. Fan (1993)
Relationship between EGF-R, c-erbB-2 protein expression and Ki67 immunostaining in breast cancer and hormone sensitivity.
R. Nicholson (1993)
Differentiation or immune destruction: two pathways for therapy of squamous cell carcinomas with antibodies to the epidermal growth factor receptor.
H. Modjtahedi (1994)
Tumor epidermal growth factor receptor studies in patients with non-small-cell lung cancer or head and neck cancer treated with monoclonal antibody RG 83852.
R. Pérez-Soler (1994)
A specific inhibitor of the epidermal growth factor receptor tyrosine kinase.
D. Fry (1994)
Antibody-induced epidermal growth factor receptor dimerization mediates inhibition of autocrine proliferation of A431 squamous carcinoma cells.
Z. Fan (1994)
Kinase-deficient neu proteins suppress epidermal growth factor receptor function and abolish cell transformation.
X. Qian (1994)
Prognostic influence of the co-expression of epidermal growth factor receptor and c-erbB-2 protein in human lung adenocarcinoma.
M. Tateishi (1994)
Epidermal growth factor-related peptides and their receptors in human malignancies.
D. Salomon (1995)
Aberrant expression of p53 or the epidermal growth factor receptor is frequent in early bronchial neoplasia and coexpression precedes squamous cell carcinoma development.
V. Rusch (1995)
Epithelial immaturity and multiorgan failure in mice lacking epidermal growth factor receptor
P. Miettinen (1995)
Single-chain antibody-mediated intracellular retention of ErbB-2 impairs Neu differentiation factor and epidermal growth factor signaling.
D. Graus-Porta (1995)
Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model.
N. Goldstein (1995)
Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors.
D. Moscatello (1995)
Apoptosis induced by an anti-epidermal growth factor receptor monoclonal antibody in a human colorectal carcinoma cell line and its delay by insulin.
X. Wu (1995)
Targeted disruption of mouse EGF receptor: effect of genetic background on mutant phenotype.
D. Threadgill (1995)
Synergistic interaction of the Neu proto-oncogene product and transforming growth factor alpha in the mammary epithelium of transgenic mice.
W. Muller (1996)
Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer.
J. Baselga (1996)
ErbB‐2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer.
D. Karunagaran (1996)
Patterns of epidermal growth factor receptor amplification in malignant gliomas.
G. Sauter (1996)
Anti-epidermal growth factor receptor monoclonal antibody 225 up-regulates p27KIP1 and induces G1 arrest in prostatic cancer cell line DU145.
D. Peng (1996)
Increased epidermal growth factor receptor expression in metaplastic bronchial epithelium.
J. Kurie (1996)
Clinical experience with CD64-directed immunotherapy. An overview
R. T. Curnow (1997)
Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors.
A. Petit (1997)
Unliganded Epidermal Growth Factor Receptor Dimerization Induced by Direct Interaction of Quinazolines with the ATP Binding Site*
C. L. Arteaga (1997)
Reciprocal changes in p27(Kip1) and p21(Cip1) in growth inhibition mediated by blockade or overstimulation of epidermal growth factor receptors.
Z. Fan (1997)
Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase.
J. D. Moyer (1997)
ErbB‐2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling
D. Graus-Porta (1997)
Levels of TGF-α and EGFR Protein in Head and Neck Squamous Cell Carcinoma and Patient Survival
J. Grandis (1998)
Evaluation of epidermal growth factor-related growth factors and receptors and of neoangiogenesis in completely resected stage I-IIIA non-small-cell lung cancer: amphiregulin and microvessel count are independent prognostic indicators of survival.
G. Fontanini (1998)
A strain‐independent postnatal neurodegeneration in mice lacking the EGF receptor
M. Sibilia (1998)
Anti-(epidermal growth factor) receptor monoclonal antibodies for the induction of antibody-dependent cell-mediated cytotoxicity against squamous cell carcinoma lines of the head and neck
H. Bier (1998)
Removal of the Membrane-anchoring Domain of Epidermal Growth Factor Leads to Intracrine Signaling and Disruption of Mammary Epithelial Cell Organization
H. Wiley (1998)
Integrins induce activation of EGF receptor: role in MAP kinase induction and adhesion‐dependent cell survival
L. Moro (1998)
Augmentation of a humanized Anti-HER2 mAb 4D5 induced growth inhibition by a human-mouse chimeric anti-EGF receptor mAb C225
D. Ye (1999)
The epidermal growth factor receptor and its inhibition in cancer therapy.
J. R. Woodburn (1999)
Targeted inactivation of the EGF and amphiregulin genes reveals distinct roles for EGF receptor ligands in mouse mammary gland development.
N. Luetteke (1999)
Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck.
S. Huang (1999)
Combination of EGFR, HER-2/neu, and HER-3 is a stronger predictor for the outcome of oral squamous cell carcinoma than any individual family members.
W. Xia (1999)
Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor.
F. Ciardiello (2000)
Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin.
J. Baselga (2000)
Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma.
C. Bruns (2000)
Radiosensitization of human breast cancer cells by a novel ErbB family receptor tyrosine kinase inhibitor.
G. S. Rao (2000)
Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors.
J. Sampson (2000)
Tumor-inhibitory antibodies to HER-2/ErbB-2 may act by recruiting c-Cbl and enhancing ubiquitination of HER-2.
L. Klapper (2000)
Site-directed irreversible inhibitors of the erbB family of receptor tyrosine kinases as novel chemotherapeutic agents for cancer.
D. W. Fry (2000)
Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(phenylamino)quinazoline- and 4-(phenylamino)pyrido[3,2-d]pyrimidine-6-acrylamides bearing additional solubilizing functions.
J. Smaill (2000)
Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(Phenylamino)quinazoline- and 4-(Phenylamino)pyrido
ErbB2 Potentiates Breast Tumor Proliferation through Modulation of p27Kip1-Cdk2 Complex Formation: Receptor Overexpression Does Not Determine Growth Dependency
H. Lane (2000)
Production of macrophage-activated killer cells for targeting of glioblastoma cells with bispecific antibody to FcγRI and the epidermal growth factor receptor
P. Wallace (2000)
Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase.
F. Sirotnak (2000)
Combinatorial chemoprevention of intestinal neoplasia
C. Torrance (2000)
Reversible G1 Arrest Induced by Inhibition of the Epidermal Growth Factor Receptor Tyrosine Kinase Requires Up-regulation of p27KIP1 Independent of MAPK Activity*
D. Busse (2000)
Blockade of the epidermal growth factor receptor tyrosine kinase suppresses tumorigenesis in MMTV/Neu + MMTV/TGF-alpha bigenic mice.
A. E. Lenferink (2000)
Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis.
A. Viloria-Petit (2001)
Activated extracellular signal-regulated kinases: association with epidermal growth factor receptor/transforming growth factor alpha expression in head and neck squamous carcinoma and inhibition by anti-epidermal growth factor receptor treatments.
J. Albanell (2001)
The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells.
M. Moasser (2001)
Signaling-inactive epidermal growth factor receptor/ligand complexes in intact carcinoma cells by quinazoline tyrosine kinase inhibitors.
R. Lichtner (2001)
Monoclonal antibody 806 inhibits the growth of tumor xenografts expressing either the de2-7 or amplified epidermal growth factor receptor (EGFR) but not wild-type EGFR.
R. Luwor (2001)
Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies.
M. Hidalgo (2001)
High levels of HER-2 expression alter the ability of epidermal growth factor receptor (EGFR) family tyrosine kinase inhibitors to inhibit EGFR phosphorylation in vivo.
J. Christensen (2001)
The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo.
D. W. Rusnak (2001)
Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor.
F. Ciardiello (2001)
Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.
S. Moulder (2001)
The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification.
N. Prenzel (2001)
The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia.
C. L. Arteaga (2001)
ZD1839 (Iressa), a novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, potently inhibits the growth of EGFR‐positive cancer cell lines with or without erbB2 overexpression
N. Anderson (2001)
Clinical trial with escalating doses of the antiepidermal growth factor receptor humanized monoclonal antibody EMD 72 000 in patients with advanced squamous cell carcinoma of the larynx and hypopharynx
H. Bier (2001)
Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition.
J. Albanell (2002)
Brain tumors in mice are susceptible to blockade of epidermal growth factor receptor (EGFR) with the oral, specific, EGFR-tyrosine kinase inhibitor ZD1839 (iressa).
A. Heimberger (2002)
Drug‐induced ubiquitylation and degradation of ErbB receptor tyrosine kinases: implications for cancer therapy
A. Citri (2002)
Effect of epidermal growth factor receptor tyrosine kinase inhibition on epithelial proliferation in normal and premalignant breast.
K. C. Chan (2002)
Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling.
A. Chakravarti (2002)
Therapeutic potential of ABX-EGF: a fully human anti-epidermal growth factor receptor monoclonal antibody for cancer treatment.
D. H. Lynch (2002)
Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts.
M. Prewett (2002)
Activation of BAD by Therapeutic Inhibition of Epidermal Growth Factor Receptor and Transactivation by Insulin-like Growth Factor Receptor*
A. Gilmore (2002)
Growth inhibitory effects of the dual ErbB1/ErbB2 tyrosine kinase inhibitor PKI-166 on human prostate cancer xenografts.
I. Mellinghoff (2002)
ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy.
A. Wakeling (2002)
EGFR is a transducer of the urokinase receptor initiated signal that is required for in vivo growth of a human carcinoma.
D. Liu (2002)
Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types.
J. Baselga (2002)
The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides.
A. Motoyama (2002)
Importance of epidermal growth factor receptor signaling in establishment of adenomas and maintenance of carcinomas during intestinal tumorigenesis
R. Roberts (2002)
ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial.
M. Ranson (2002)
Blockade of the epidermal growth factor receptor signaling inhibits angiogenesis leading to regression of human renal cell carcinoma growing orthotopically in nude mice.
D. Kedar (2002)
Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].
M. Fukuoka (2003)
Therapeutic potential of chimeric and murine anti-(epidermal growth factor receptor) antibodies in a metastasis model for human melanoma
M. Naramura (2005)
This paper is referenced by
Human blood serum can donor-specifically antagonize effects of EGFR-targeted drugs on squamous carcinoma cell growth
D. Kamashev (2021)
The mineralocorticoid receptor leads to increased expression of EGFR and T-type calcium channels that support HL-1 cell hypertrophy
Katharina Stroedecke (2021)
Cetuximab in locally advanced head and neck squamous cell carcinoma: biological mechanisms involved in efficacy, toxicity and resistance.
E. Muraro (2021)
SGCE Promotes Breast Cancer Stem Cells by Stabilizing EGFR
Lina Zhao (2020)
PanErbB-targeted CAR T-cell immunotherapy of head and neck cancer
Daniel Larcombe-Young (2020)
CRKL regulates alternative splicing of cancer-related genes in cervical cancer samples and HeLa cell
Qingling Song (2019)
Ligand binding effects on the activation of the EGFR extracellular domain.
Q. Shao (2019)
Rethink of EGFR in Cancer With Its Kinase Independent Function on Board
R. Thomas (2019)
Proximity proteomics identifies cancer cell membrane cis‐molecular complex as a potential cancer target
N. Kotani (2019)
Activatable fluorescence detection of epidermal growth factor receptor positive mediastinal lymph nodes in murine lung cancer model
Xieyi Zhang* (2018)
Cetuximab combined with natural killer cells therapy: an alternative to chemoradiotherapy for patients with advanced non-small cell lung cancer (NSCLC).
Shuzhen Liang (2018)
Proximity proteomics identifies cancer cell membrane cis-molecular complex as a potential cancer target
N. Kotani (2018)
EGFR signaling pathways are wired differently in normal 184A1L5 human mammary epithelial and MDA-MB-231 breast cancer cells
Zachary Speth (2017)
HER Family Receptors are Important Theranostic Biomarkers for Cervical Cancer: Blocking Glucose Metabolism Enhances the Therapeutic Effect of HER Inhibitors
Olga Martinho (2017)
Cancer Biology and the Principles of Targeted Cancer Drug Discovery
Petra Hillmann (2017)
Curcumin co-treatment ameliorates resistance to gefitinib in drug- resistant NCI-H1975 lung cancer cells.
X. Jin (2017)
Evaluación de CIMAvaxEGF para el tratamiento del cáncer de pulmón: meta-análisis de ensayos clínicos controlados
C. Viada (2017)
Highly Specific and Effective Targeting of EGFRvIII-Positive Tumors with TandAb Antibodies
K. Ellwanger (2017)
Receptor tyrosine kinase expression and phosphorylation in canine nasal carcinoma.
Samuel E Hocker (2017)
Clinical development and Perspectives of CImAvax EgF,
P. C. Rodríguez (2017)
RAF-MEK-MAPK Pathway Targeted by Tumor Suppression and Anticancer Therapeutic Agents
X. Zhang (2017)
ErbB activation signatures as potential biomarkers for anti-ErbB3 treatment in HNSCC
D. Alvarado (2017)
Brain Metastases from Breast Cancer in Patients Receiving Trastuzumab
R. Duchnowska (2016)
Chapter 9 – Principles of Chemotherapy
Benjamin Izar (2016)
Epidermal Growth Factor Receptor and Ki-67 Expression in Canine Gliomas
A. Fraser (2016)
Tumor-suppressive miR-218-5p inhibits cancer cell proliferation and migration via EGFR in non-small cell lung cancer
Kegan Zhu (2016)
Granzyme B inhibits keratinocyte migration by disrupting epidermal growth factor receptor (EGFR)-mediated signaling
Y. Merkulova (2016)
The application of mathematical modelling to the design of bispecific monoclonal antibodies
T. V. van Steeg (2016)
Treatment of HER2-Overexpressing Metastatic Breast Cancer
A. Aydıner (2016)
Correlation of Musashi-1, Lgr5, and pEGFR expressions in human small intestinal adenocarcinomas
Yan Wang (2015)
An overview of experimental and investigational multikinase inhibitors for the treatment of metastatic colorectal cancer
Y. C. Lee (2015)
Molecular Biology of Urothelial Cancer
S. Gupta (2015)See more